Q-omics provides the consensus-scored DOK6 profile across patient tissues and cancer cell-line models. DOK6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DOK6 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, DOK6 RNA expression shows 21,101 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, BLCA, and PDAC as cancer lineages where DOK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOK6 survival associations across molecular data types. DOK6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOK6 RNA expression–survival associations across cancer types. High DOK6 expression shows unfavorable associations in UVM, BLCA, STAD and KIRP, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DOK6 RNA expression.
This table summarizes DOK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DOK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOK6 shows lower tumor expression in BLCA, KICH, THCA, LUSC and LUAD and higher tumor expression in BRCA. The BLCA box plot shows higher DOK6 RNA expression in normal versus tumor tissue (log2 FC = −2.951, t-test p < 0.001).
This table shows molecular features associated with DOK6 in patient tissues and cancer cell lines. In patient samples, DOK6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DOK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
